Table 1

Baseline characteristics according to quartiles of baseline hsCRP

Variable
hsCRP (mg/L)
Quartiles of baseline hsCRPp ANOVA
1st quartile
0.00–0.90
2nd quartile
0.90–2.15
3rd quartile
2.15–4.50
4th quartile
4.50–15.80
Age (year)66±1067±1069±968±9<0.001
Female sex (n, %)144 (34.1)142 (34.5)162 (41.8)178 (44.9)0.002
Smoking (n, %)
 Current62 (14.7)77 (18.7)74 (19.1)91 (23)0.03
 Former150 (35.5)147 (35.7)144 (37.1)143 (36.1)0.97
 Never210 (49.8)188 (45.6)170 (43.8)162 (40.9)0.08
Hypertension342 (81)355(86.2)338(87.1)362(91.4)<0.001
Randomised treatment (n, %)207 (49.1)219 (53.2)214 (55.2)180 (45.5)0.03
Systolic BP (mm Hg)143±0146±20144±20146±200.045
Diastolic BP (mm Hg)81±1083±1082±1182±100.36
Body mass index (kg/m2)25±427±428±429±5<0.001
Left ventricular mass index (g/m2)99.26±30.3102.07±30.72102.6±32.89104.6±32.620.12
Left ventricular ejection fraction (%)66.41±8.2165.71±8.5465.33±7.7665.43±8.530.25
Aortic valve area index (cm2/m2)0.73±0.270.69±0.280.68±0.260.68±0.250.046
Aortic valve peak velocity (m/s)3.25±0.643.24±0.653.27±0.653.25±0.640.96
Concomitant treatment
 ACE inhibitor80 (19)126 (30.6)108 (27.8)134 (33.8)<0.001
 Angiotensin II receptor blocker72 (17.1)82 (19.9)67 (17.3)86 (21.7)0.272
 Calcium antagonist83 (19.7)111 (26.9)111 (28.6)152 (38.4)<0.001
 Aspirin or other platelet inhibitor182 (43.1)182 (44.2)164 (42.3)191 (48.2)0.34
 β-Blocker173 (41)212 (51.5)202 (52.1)208 (52.5)0.002
  • ANOVA, analysis of variance; BP, blood pressure; hsCRP, high-sensitive C reactive protein.